AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions, and listings, of claims in the application.

Claims 1-54 (Canceled).

55. (Currently Amended) A di-ester derivative of camptothecin having the following general structure:

wherein

 R_1 , R_2 , R_3 , and R_4 , which can be the same or different, are hydrogen, halogen, C_1 – C_{20} alkyl, C_1 – C_8 alkoxyl, C_4 - C_{20} aryl or C_1 - C_{20} silyl,

each R can be the same or different and is $[[C_1-C_{30}]]$ $\underline{C_2-C_{30}}$ alkyl, C_2 $-C_{22}$ alkenyl, C_4 - C_{30} aryl, $(CH_2)_nOR_5$, $(CH_2)_nSR_5$, $(CH_2)_nNR_5R_6$ or $(CH_2)_nCOR_7$,

wherein,

 R_5 and R_6 , which can be the same or different, are C_1 – C_8 alkyl[[,]] or C_2 – C_6 alkenyl [[or C_4 - C_{10} aryl]],

 $R_7 \ is \ hydroxy, C_1-C_{20} \ alkyl, C_1-C_6 \ alkenyl, C_1-C_6 \ alkoxy, C_4-C_{20} \ aryl, or \\ NR_8R_9,$

wherein,

 R_8 and R_9 , which can be the same or different, are C_1 - C_6 alkyl, and n is an integer of 1 to 8,

or a pharmaceutically acceptable salt thereof.

56. (Currently Amended) A di-ester derivative of claim 55 or a salt thereof wherein each R can be the same or different and is $[[C_1-C_{20}]]$ $\underline{C_2-C_{20}}$ alkyl, C_2-C_6 alkenyl, or C_4-C_{20} aryl.

- 57. (Previously Presented) A pharmaceutical composition comprising an effective amount of the camptothecin di-ester derivative of claim 55 or a salt thereof and a pharmaceutically acceptable carrier or diluent.
- 58. (Previously Presented) A pharmaceutical composition comprising an effective amount of the camptothecin di-ester derivative of claim 56 or a salt thereof and a pharmaceutically acceptable carrier or diluent.
- 59. (Currently Amended) The di-ester derivative of claim 55, wherein each of R_1 , R_2 , R_3 , and R_4 is H, and R is $[[C_3-C_{30}]]$ $\underline{C_2-C_{30}}$ alkyl.
- 60. (Currently Amended) The di-ester derivative of claim 56, wherein each of R_1 , R_2 , R_3 , and R_4 is H, and R is $[[C_1-C_{20}]]$ $\underline{C_2-C_{20}}$ alkyl.
- 61. (Previously Presented) The di-ester derivative of claim 55, wherein each of R_1 , R_2 , R_3 , and R_4 is H, and R is C_2 - C_{22} alkenyl.
- 62. (Previously Presented) The di-ester derivative of claim 56, wherein each of R_1 , R_2 , R_3 , and R_4 is H, and R is C_2 - C_6 alkenyl.
- 63. (Currently Amended) The di-ester derivative of claim 55, wherein each of R_1 , R_2 , R_3 and R_4 is H, and R is $(CH_2)_nOR_5$,

wherein,

$$R_5$$
 is C_1 – C_6 alkyl[[,]] or C_2 – C_6 alkenyl [[, or C_4 - C_{10} aryl]], and n is 1 or 2.

64. (Currently Amended) The di-ester derivative of claim 55, wherein each of R_1 , R_2 , R_3 and R_4 is H, and R is $(CH_2)_nSR_5$,

wherein.

$$R_5$$
 is C_1 – C_6 alkyl[[,]] or C_2 – C_6 alkenyl [[, or C_4 - C_{10} aryl]], and n is 1 or 2.

65. (Currently Amended) The di-ester derivative of claim 55 or a salt thereof, wherein each of R₁, R₂, R₃ and R₄ is H, and R is [[(CH₂)nNR5R6]] (CH₂)_nNR₅R₆,

 R_5 and R_6 are independently, C_1 – C_6 alkyl[[,,]] or C_2 – C_6 alkenyl [[, or C_4 - C_{10} aryl]], and n is 1 or 2.

66. (Previously Presented) The di-ester derivative of claim 55, wherein each of R_1 , R_2 , R_3 and R_4 is H, and R is $(CH_2)_nCOR_7$,

wherein,

 R_7 is hydroxy, C_1 – C_6 alkyl, C_2 – C_6 alkenyl, or C_4 - C_{10} aryl, and n is 2 to 4.

- 67. (Currently Amended) The di-ester derivative of claim 55, wherein each of R_1 , R_2 and R_3 is H, R_4 is CH_2CH_3 and R is $[[C_1-C_{30}]]$ $\underline{C_2-C_{30}}$ alkyl.
- 68. (Currently Amended) The di-ester derivative of claim 56, wherein each of R_1 , R_2 and R_3 is H, R_4 is CH_2CH_3 , and R is $[[C_1-C_{20}]]$ $\underline{C_2-C_{20}}$ alkyl.
- 69. (Previously Presented) The di-ester derivative of claim 55, wherein each of R_1 , R_2 and R_3 is H, R_4 is CH_2CH_3 , and R is C_2-C_{22} alkenyl.
- 70. (Previously Presented) The di-ester derivative of claim 56, wherein each of R_1 , R_2 and R_3 is H, R_4 is CH_2CH_3 , and R is C_2 – C_6 alkenyl.
- 71. (Previously Presented) The di-ester derivative of claim 55, wherein each of R_1 , R_2 and R_3 is H, R_4 is CH_2CH_3 and R is C_4-C_{30} aryl.
- 72. (Previously Presented) The di-ester derivative of claim 56, wherein each of R_1 , R_2 and R_3 is H, R_4 is CH_2CH_3 , and R is C_4-C_{20} aryl.
- 73. (Currently Amended) The di-ester derivative of claim 55, wherein each of R_1 , R_2 and R_3 is H, R_4 is CH_2CH_3 , and R is $(CH_2)_nOR_5$,

wherein,

$$R_5$$
 is C_1 – C_6 alkyl[[,]] or C_2 – C_6 alkenyl [[, or C_4 - C_{10} aryl]], and n is 1 or 2.

74. (Previously Presented) The di-ester derivative of claim 55, wherein each of R_1 , R_2 and R_3 is H, R_4 is CH_2CH_3 and R is $(CH_2)_nSR_5$,

wherein.

 R_5 is C_1 – C_6 alkyl, C_2 – C_6 alkenyl, or C_4 - C_{10} aryl, and n is 1 or 2.

75. (Currently Amended) The di-ester derivative of claim 55 or a salt thereof, wherein each of R₁, R₂ and R₃ is H, R₄ is CH₂CH₃, and R is (CH₂)_nNR₅R₆,

wherein,

 R_5 and R_6 are independently, C_1 – C_6 alkyl[[,]] or C_2 – C_6 alkenyl [[, or C_4 - C_{10} aryl]], and n is 1 or 2.

76. (Currently Amended) The di-ester derivative of claim 55, wherein each of R_1 , R_2 and R_3 is H, R_4 is CH_2CH_3 , and R_3 is $[CH_2]_nCOR_7$ ($CH_2]_nCOR_7$)

wherein,

 R_7 is hydroxy, C_1 – C_6 alkyl, C_2 – C_6 alkenyl, or C_4 - C_{10} aryl, and n is 2 to 4.

- 77. (Currently Amended) The di-ester derivative of claim 55, wherein each of R_1 , R_2 and R_3 is H, R_4 is $Si(CH_3)_2C(CH_3)_3$, and R is $[[C_1-C_{30}]]$ C_2-C_{30} alkyl.
- 78. (Currently Amended) The di-ester derivative of claim 56, wherein each of R_1 , R_2 and R_3 is H, R_4 is $Si(CH_3)_2C(CH_3)_3$, and R is $[[C_1-C_{20}]]$ C_2-C_{20} alkyl.
- 79. (Previously Presented) The di-ester derivative of claim 55, wherein each of R_1 , R_2 and R_3 is H, R_4 is $Si(CH_3)_2C(CH_3)_3$, and R is C_2-C_{22} alkenyl.
- 80. (Previously Presented) The di-ester derivative of claim 56, wherein each of R_1 , R_2 and R_3 is H, R_4 is $Si(CH_3)_2C(CH_3)_3$, and R is C_2 – C_6 alkenyl.
- 81. (Currently Amended) [[The]] <u>The</u> di-ester derivative of claim 55, wherein each of R_1 , R_2 and R_3 is H, R_4 is $Si(CH_3)_2C(CH_3)_3$, and R is C_4 - C_{30} aryl.
- 82. (Currently Amended) The di-ester derivative of claim 56, wherein each of R_1 , R_2 and R_3 is H, R_4 is $[[Si(_{CH3})_2C(CH_3)_3]]$ $\underline{Si(CH_3)_2C(CH_3)_3}$, and R is C_4 - C_{20} aryl.
- 83. (Currently Amended) The di-ester derivative of claim 55, wherein each of R_1 , R_2 and R_3 is H, R_4 is $Si(CH_3)_2C(CH_3)_3$, and R is $(CH_2)_nOR_5$;

 R_5 is C_1 – C_6 alkyl[[,]] or C_2 – C_6 alkenyl [[, or C_4 - C_{10} aryl]], and n is 1 or 2.

84. (Previously Presented) The di-ester derivative of claim 55, wherein each of R₁, R₂ and R₃ is H, R₄ is Si(CH₃)₂C(CH₃)₃, and R is (CH₂)_nSR₅,

wherein.

$$R_5$$
 is C_1 – C_6 alkyl, C_2 – C_6 alkenyl, or C_4 - C_{10} aryl, and n is 1 or 2.

85. (Currently Amended) The di-ester derivative of claim 55 or a salt thereof, wherein each of R₁, R₂ and R₃ is H, R₄ is Si(CH₃)₂C(CH₃)₃, and R is (CH₂)_nNR₅R₆,

wherein,

 R_5 and R_6 are independently, C_1 – C_6 alkyl[[,,]] or C_2 – C_6 alkenyl [[, or C_4 - C_{10} aryl]], and n is 1 or 2.

86. (Previously Presented) The di-ester of claim 55, wherein each of R_1 , R_2 and R_3 is H, R_4 is $Si(CH_3)_2C(CH_3)_3$, and R is $CH_2)_nCOR_7$.

$$R_7$$
 is hydroxy, C_1 – C_6 alkyl, C_2 – C_6 alkenyl, or C_4 - C_{10} aryl, and n is 2 to 4.

- 87. (Currently Amended) The di-ester derivative of claim 55 or a salt thereof, wherein R_1 is $CH_2N(CH_3)_2$, each of R_2 , R_3 and R_4 is H_3 , and R_4 is H_4 is H_5 , and H_6 is H_7 .
- 88. (Currently Amended) The di-ester derivative of claim 56 or a salt thereof, wherein R_1 is $CH_2N(CH_3)_2$, each of R_2 , R_3 and R_4 is H, and R is $[[C_1-C_{20}]]$ $\underline{C_2-C_{20}}$ alkyl.
- 89. (Previously Presented) The di-ester derivative of claim 55 or a salt thereof, wherein R_1 is $CH_2N(CH_3)_2$, each of R_2 , R_3 and R_4 is H_3 , and H_4 is H_5 is H_5 .
- 90. (Previously Presented) The di-ester derivative of claim 56 or a salt thereof, wherein R_1 is $CH_2N(CH_3)_2$, each of R_2 , R_3 and R_4 is H_3 , and H_4 is H_5 and H_6 is H_6 alkenyl.
- 91. (Previously Presented) The di-ester derivative of claim 55 or a salt thereof, wherein R_1 is $CH_2N(CH_3)_2$, each of R_2 , R_3 and R_4 is H, and R is C_4 - C_{30} aryl.

- 92. (Previously Presented) The di-ester derivative of claim 56 or a salt thereof, wherein R_1 is $CH_2N(CH_3)_2$, each of R_2 , R_3 and R_4 is H, and R is C_4 - C_{20} aryl.
- 93. (Currently Amended) The di-ester derivative of claim 55 or a salt thereof, wherein R₁ is CH₂N(CH₃)₂, each of R₂, R₃ and R₄ is H, and R is (CH₂)_nOR₅,

wherein,

$$R_5$$
 is C_1 – C_6 alkyl[[,]] or C_2 – C_6 alkenyl [[, or C_4 - C_{10} aryl]], and n is 1 or 2.

94. (Previously Presented) The di-ester derivative of claim 55 or a salt thereof, wherein R_1 is $CH_2N(CH_3)_2$, each of R_2 , R_3 and R_4 is H, and R is $(CH_2)_nSR_5$,

wherein,

$$R_5$$
 is C_1 – C_6 alkyl, C_2 – C_6 alkenyl, or C_4 - C_{10} aryl, and n is 1 or 2.

95. (Currently Amended) The di-ester derivative of claim 55 or a salt thereof, wherein R₁ is CH₂N(CH₃)₂, each of R₂, R₃ and R₄ is H, and R is (CH₂)_nNR₅R₆,

wherein,

 R_5 and R_6 are independently, C_1 – C_6 C_1 – C_6 alkyl[[,]] or C_2 – C_6 alkenyl [[, or C_4 - C_{10} aryl]], and n is 1 or 2.

96. (Previously Presented) The di-ester derivative of claim 55 or a salt thereof, wherein R_1 is $CH_2N(CH_3)_2$, each of R_2 , R_3 and R_4 is H, and R is $(CH_2)_nCOR_7$,

$$R_7$$
 is hydroxy, C_1 – C_6 alkyl, C_2 – C_6 alkenyl, or C_4 - C_{10} aryl, and n is 2 to 4.

- 97. (Currently Amended) A method <u>of inhibiting</u> [[to inhibit]] the enzyme topoisomerase I in an animal in need thereof comprising administering to the animal an effective amount of a composition comprising at least one di-ester derivative of claim 55.
- 98. (Currently Amended) A method <u>of inhibiting</u> [[to inhibit]] the enzyme topoisomerase I in an animal in need thereof comprising administering to the animal an effective amount of a composition comprising at least one di-ester derivative of claim 56.

- 99. (Currently Amended) A method of treating [[to treat]] cancer in a patient comprising administering a composition comprising at least one di-ester derivative of claim 55 to said patient in an effective amount to treat said cancer.
- 100. (Currently Amended) A method of treating [[to treat]] cancer in a patient comprising administering a composition comprising at least one di-ester derivative of claim 56 to said patient in an effective amount to treat said cancer.
- 101. (Previously Presented) The method of claim 99, wherein said cancer is lung, breast, colon, prostate, melanoma, pancreas, stomach, liver, brain, kidney, uterus, cervix, ovaries, urinary tract, gastrointestinal, or leukemia.
- 102. (Previously Presented) The method of claim 100, wherein said cancer is lung, breast, colon, prostate, melanoma, pancreas, stomach, liver, brain, kidney, uterus, cervix, ovaries, urinary tract, gastrointestinal, or leukemia.
- 103. (Previously Presented) The method of claim 99, wherein said cancer is solid tumor or blood borne tumor.
- 104. (Previously Presented) The method of claim 100, wherein said cancer is solid tumor or blood borne tumor.
- 105. (Previously Presented) The method of claim 99, wherein said composition is administered orally, parenterally, intramuscularly, transdermally or by an airborne delivery system.
- 106. (Previously Presented) The method of claim 100, wherein said composition is administered orally, parenterally, intramuscularly, transdermally or by an airborne delivery system.
- 107. (Previously Presented) The method of claim 99, wherein said composition is a nanoparticle containing said at least one di-ester of camptothecin.
- 108. (Previously Presented) The method of claim 100, wherein said composition is a nanoparticle containing said at least one di-ester of camptothecin.